Anastrozole, Trastuzumab and Tamoxifen – The Custodians of Breast Cancer Therapy

Breast cancer is the most common cancer in women in the world however, huge progress has been made in relation to diagnosis and treatment. A huge area where this has become possible is in genetic screening for bio-marker genes such as BRCA1, which can predict an increased likelihood in developing breast cancer whereby preventative chemotherapy or surgery could be conducted to the patient’s request. Following biopsy and confirmation of malignant tissue, the presence or absence of drug targets can be elucidated and from there the patient’s optimum drug therapy can be determined.

Molecular biology has elucidated key receptors, which have been targeted by drugs in breast Breat Cancer Anastrazole Imagecancer treatment. This allows for the most accurate treatment in digressing the breast cancer displayed, as well as helping to reduce the burden, which needs to be tackled using further surgery, radiotherapy or chemotherapy. Most breast cancers are hormone receptor positive – meaning that malignant cell growth in the breast is promoted by Estrogen, which should occur to stimulate breast tissue during ovulation and pregnancy. However, receptor activation leads to a cascade of excessive tissue growth and is the reason that estrogen hormone replacement therapy (HRT) has also been found as a link to breast cancer. Estrogen receptor positive (ER+) cancer can be identified via genetic analysis from biopsy screening, and multiple regimens can then be pursued.

Anastrozole _breast_cancerAromatase inhibitors the enzyme which blocks the final step of estrogen synthesis, which involves the aromatisation of the steroid ring A in testosterone as well as from androsteinedione to Estrone, an estrogen precursor. This reduces endogenous estrogen levels, which regulate cell growth rates. Anastrozole is indicated as the first line treatment in adjuvant therapy of ER + breast cancer in postmenopausal women by the British National Formulary, which prevents further inappropriate cell division and should be maintained for five years following treatment.

Tamoxifen is considered the first line adjuvant treatment in pre-menopausal women with estrogen positive breast cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which promotes positive estrogenic effects such as bone mineralisation while antagonising estrogen binding activity in desirable target areas such as breast tissue. Tamoxifen has also shown to potentiate some aromatase inhibition activity, which was recently published via a metabolite, norendoxifen, which potentially could serve as a promising lead compound. Tamoxifen for five years followed by a further two years on the aromatase inhibitor Letrozole is also indicated in postmenopausal women who require more intensive or extended adjuvant therapy.

Tamoxifen, Anastrozole and Letrozole are available as tablets through Taj Accura, which is preferred by patients as opposed to a parenteral alternative, particularly when the long term treatment regimen is factored into account.

anti_cancerHuman epidermal growth factor 2 (HER2) expression on breast cancer cells has also been indicated heavily as a biomarker, although not as abundant as ER breast cancers. HER2 over expression is due to a non-familial genetic mutation, and belongs to the epidermal growth factor family of genes which has been linked to a multitude of other cancers. HER2 treatment primarily is conducted using the revolutionary drug Trastuzumab, which since its launch in 1998 by Genentech, a UCLA spinoff company. Trastuzumab has significantly increased survival rates for HER2 positive patients in comparison to previous, less specific chemotherapeutic regimens such as 5-fluorouracil and high dose Methotrexate. Trastuzumab is indicated in the treatment of early HER2 positive breast cancer, in conjunction to surgery, radiotherapy and chemotherapy where applicable. Although HER2 resistance can ensue during treatment, recent advances in research have identified a new biomarker which could potentially predict such activity in breast cancer and indicate the choice of a more rigorous drug regimen in the future.

Taj Accura believes that pharmaceutical health care for patients should be offered for the most competitive cost, allowing the health care provider to provide additional health care services. Generic equivalents of Anastrozole, Aamoxifen, Letrozole and Trastuzumab are available to an international market at the most competitive prices via Taj Accura, where our bi-lingual sales team can assist in regulatory measures from expertise. We also have a large portfolio in other oncology products, as well as targeting generic products for the cardiovascular and central nervous system, as well as a suite of nutraceutical products.

Anastrozole, Trastuzumab and Tamoxifen – The Custodians of Breast Cancer Therapy – Taj Dearob Pharma | Breast cancer is the most common cancer in women in the world however, huge progress has been made in relation to diagnosis and treatment. A huge area where this has become possible is in genetic screening for bio-marker genes such as BRCA1, which can predict an increased likelihood in developing breast cancer whereby preventative chemotherapy or surgery could be conducted to the patient’s request.
Anastrozole, Trastuzumab and Tamoxifen – The Custodians of Breast Cancer Therapy – Taj Dearob Pharma | Breast cancer is the most common cancer in women in the world however, huge progress has been made in relation to diagnosis and treatment. A huge area where this has become possible is in genetic screening for bio-marker genes such as BRCA1, which can predict an increased likelihood in developing breast cancer whereby preventative chemotherapy or surgery could be conducted to the patient’s request.